Achieve Life Sciences (ACHV) Change in Interest Receivables (2012 - 2017)
Achieve Life Sciences' (ACHV) quarterly Change in Interest Receivables came in at -$32000.0 in Q1 2017, up 44.83% YoY from -$22095.2 in Q1 2016, and down 700.0% on a QoQ basis from -$4000.0 in Q4 2016.
Achieve Life Sciences (ACHV) Change in Interest Receivables (2012 - 2017) Analysis & Trends
Achieve Life Sciences (ACHV) has 6 years of Change in Interest Receivables data on file, last reported at -$32000.0 in Q1 2017.
- Quarterly Change in Interest Receivables rose 44.83% year-over-year to -$32000.0 in Q1 2017, while the trailing twelve-month figure through Jun 2017 was -$47000.0 (down 62.07% YoY) and the FY2016 annual result came in at -$79000.0, down 3850.0% from the prior year.
- Change in Interest Receivables retreated to -$32000.0 in Q1 2017, from -$4000.0 in the prior quarter.
- In the past five years, Change in Interest Receivables ranged from a high of $94000.0 in Q4 2014 to a low of -$166000.0 in Q2 2014.
- A 5-year average of -$19235.3 and a median of -$11000.0 in 2016 frame the typical range for Change in Interest Receivables.
- The widest YoY moves for Change in Interest Receivables: up 480.0% in 2014, down 766.67% in 2014.
- Tracing ACHV's Change in Interest Receivables over 5 years: stood at -$77000.0 in 2013, then jumped by 222.08% to $94000.0 in 2014, then plunged by 32.98% to $63000.0 in 2015, then plunged by 106.35% to -$4000.0 in 2016, then tumbled by 700.0% to -$32000.0 in 2017.
- The last three Change in Interest Receivables figures came in at -$32000.0 (Q1 2017), -$4000.0 (Q4 2016), and -$11000.0 (Q3 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | -32,000.00 |
| Dec 31, 2016 | -4,000.00 |
| Sep 30, 2016 | -11,000.00 |
| Jun 30, 2016 | -6,000.00 |
| Mar 31, 2016 | -58,000.00 |
| Dec 31, 2015 | 63,000.00 |
| Sep 30, 2015 | -28,000.00 |
| Jun 30, 2015 | 5,000.00 |
| Mar 31, 2015 | -42,000.00 |
| Dec 31, 2014 | 94,000.00 |
| Sep 30, 2014 | 19,000.00 |
| Jun 30, 2014 | -166,000.00 |
| Mar 31, 2014 | -52,000.00 |
| Dec 31, 2013 | -77,000.00 |
| Sep 30, 2013 | -5,000.00 |
| Jun 30, 2013 | -21,000.00 |
| Mar 31, 2013 | -6,000.00 |
| Dec 31, 2012 | -180,000.00 |
| Sep 30, 2012 | 35,000.00 |
| Jun 30, 2012 | 100,000.00 |